

**Renalytix plc**  
("Renalytix" or the "Company")

**Three kidneyintelX.dkd Clinical Integrations**

**LONDON and NEW YORK, 12 January 2026** Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with *kidneyintelX.dkd*, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use.

The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix.

These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations.

Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources.

**Tempus AI Collaboration**

Renalytix continues to work closely with Tempus AI, Inc. ("Tempus") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in [September 2025](#), to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients.

The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time.

**Investor Engagement**

James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes.

The 44<sup>th</sup> annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad range of healthcare and life sciences companies, including data and diagnostics partners such as Tempus.

The Company looks forward to updating investors on progress, corporate development and trading in February 2026.

***For further information, please contact:***

**Renalytix plc**

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

**SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)**

Jeff Keating / David Hignell (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Tel: +44 (0)20 3470 0470

**Oberon Capital (Joint Broker)**

Mike Seabrook / Nick Lovering

Tel: +44 (0)20 3179 5300

**About Renalytix ([www.renalytix.com](http://www.renalytix.com))**

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled *vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for *kidneyintelX.dkd* which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, *kidneyintelX.dkd* is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. *kidneyintelX.dkd* is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by *kidneyintelX.dkd* have produced a substantial body of real-world performance data. In patient populations where *kidneyintelX.dkd* has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. *kidneyintelX.dkd* now has full reimbursement established by Medicare, the largest insurance payer in the United States, at 950 per reportable result. *kidneyintelX.dkd* is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

*KidneyIntelX* is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the *kidneyintelX.dkd* test, visit [kidneyintelx.com](http://kidneyintelx.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCKZGMMLMNGVZM